Evidence map›Paper›PMID 26280620›Full record

ArticleSmall GTPases2015

Drugging the Ral GTPase.

Chao Yan, David N M Jones, Dan Theodorescu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small GTPases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Synthesis of novel Ral inhibitors: An in vitro and in vivo study.Bioorganic & medicinal chemistry letters · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Chao Yana Departments of Surgery (Urology) and Pharmacology ; University of Colorado ; Aurora , CO USA.
David N M Jones
Dan Theodorescu
University of Colorado System · USThe Medical Center of Aurora · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4M
CRYOPROBE FOR NMR STRUCTURAL STUDIES: STRUCTURAL BIOLOGY S10RR019125 · NCRR · UNIVERSITY OF COLORADO DENVER · PI JONES, DAVID NIGEL · 2004 to 2004
$234k
NCI NIH HHS CA091846NCI NIH HHS P30 CA046934NCRR NIH HHS S10 RR019125
6 · The paper itself

Abstract

The RAL GTPases have emerged as important drivers of tumor growth and metastasis in lung, colon, pancreatic and other cancers. We recently developed the first small molecule inhibitors of RAL that exhibited antitumor activity in human lung cancer cell lines. These compounds are non-competitive inhibitors that bind to the allosteric site of GDP-bound RAL. The RAL inhibitors have the potential to be used in combination therapy with other inhibitors of the RAS signaling pathway. They also provide insights toward directly targeting other GTPases.

Indexed as

Allosteric SiteAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorHumansMolecular Targeted TherapyNeoplasmsral GTP-Binding Proteinsras ProteinsSignal TransductionSmall Molecule LibrariesAntineoplastic Agentsral GTP-Binding Proteinsras ProteinsSmall Molecule LibrariesallostericGTPasemetastasispersonalized medicineprecision medicineRalRassmall moleculetargeted therapy

Identifiers

PMID26280620
PMCPMC4601353
OpenAlexW1893759010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.